Feature | March 07, 2013

Echocardiograms for Valvular Regurgitation May Be Overused

The American Society of Echocardiography joins with 16 other specialty groups—releasing a list of “Five Things Physicians and Patients Should Question” at a national event in Washington, D.C

An echocardiogram being performed on a patient using a Toshiba ultrasound system at ASE 2017. ASE offers appropriate use criteria (AUC) for echocardiograms.

This article was updated in 2018

March 7, 2013 — The American Society of Echocardiography (ASE) has released a list of five interventions whose appropriateness physicians and patients should discuss as part of Choosing Wisely, an initiative of the ABIM Foundation, along with Consumer Reports. First in the list, they ask that patients and their doctors talk about the real need for additional echocardiograms when there are only minor signs of heart valve leakage.

Do not order follow up or serial echocardiograms for surveillance after a finding of trace valvular regurgitation on an initial echocardiogram.

As access to healthcare information has become more readily available to concerned patients, a growing number of doctors have become involved in evaluating, ordering and caring for patients with a wider range of heart health problems rather than sending them directly to a specialist to follow these issues. Additionally, the technology associated with medical testing has improved and miniaturized, leading to increased utilization of echocardiography to quickly and painlessly evaluate the patient’s heart. With the increase in testing and improvements in technology, it is now common for physicians to find trace valve regurgitation, or leakage, that in the past no one would have been aware was present. This may lead to anxiety, misleading results and more questions for a patient who has a limited understanding of echo reporting.

Trace regurgitation is a very mild leak of a heart valve, which occurs when a valve does not close tightly, allowing blood to leak backward in your heart. Nearly all of the normal population will have a finding of some trivial or mild degree of regurgitation of one, two or three heart valves on a normal echocardiogram. This is sometimes called “physiologic” regurgitation by the doctor interpreting the echocardiogram. In most cases, a doctor, used to seeing these types of patients, will not even mention this finding to the patient as a way of avoiding the anxiety associated with this disclosure, which would be an essentially normal finding in most patients.

Trace, physiologic, and in most cases, mild regurgitation of the mitral, tricuspid or pulmonic valve reported on an echocardiogram requires no immediate or long term follow up. Following up on these findings with additional testing should only be done if you and your doctor believe you have signs and symptoms of the leakage progressing or getting worse. These signs may include a murmur (an abnormal sound when the doctor listens to your heart), fatigue, chest pain, shortness of breath, or extra, or funny, heart beats.

If a patient has trace regurgitation of the aortic valve, their doctor may choose to follow the regurgitation with future echocardiograms and additional physical examinations.

The goal of Choosing Wisely is to promote conversations between physicians and patients about utilizing the most appropriate tests and treatments and avoiding care that may provide no benefit.

ASE’s testing cardiovascular care scenarios were chosen based on the highest likelihood of improving patient care and reducing inappropriate test use. Leaders in the organization transformed the scenarios into plain language and produced the clinical explanations for each procedure. In particular, ASE’s cardiovascular care experts, reviewed the ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriateness Use Criteria for Echocardiography (AUC), which was published in March 2011. Here is a link to the most current version of the ASE AUC guidelines.

ASE encourages all medical professionals engaged in cardiovascular care to read the

“Five Things Physicians and Patients Should Question” lists at www.choosingwisely.org, and to engage their patients in conversations about reducing inappropriate tests and procedures with a goal of improving care and avoiding harm.

Consumer Reports, along with a coalition of consumer partner organizations, is also a part of the Choosing Wisely effort and is working with many of the societies to help patients understand the tests and treatments that are right for them.

For more information: www.asecho.org, www.choosingwisely.org

 

Related Content:

ASE Releases List of Five Tests or Procedures That May Be Overused

Top Echocardiography News and Video From ASE 2017

A Glimpse Into the Future of Cardiac Ultrasound

 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now